VYNE Therapeutics (VYNE) Divestments (2022 - 2023)
VYNE Therapeutics (VYNE) posted Divestments of $5.0 million for Q1 2023, up 499900.0% on a QoQ basis from $1000.0 in Q4 2022, and down 68.26% year-over-year from $15.8 million in Q1 2022.
VYNE Therapeutics (VYNE) Divestments (2022 - 2023) Analysis & Trends
VYNE Therapeutics' Divestments history runs 2 years deep, the most recent figure standing at $5.0 million for Q1 2023.
- Quarterly Divestments fell 68.26% year-over-year to $5.0 million in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $5.0 million (down 68.09% YoY) and the FY2023 annual result came in at $5.0 million, down 68.09% from the prior year.
- Divestments was $5.0 million for Q1 2023 at VYNE Therapeutics, up from $1000.0 in the prior quarter.
- Across five years, Divestments topped out at $15.8 million in Q1 2022 and bottomed at -$86000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -32.58 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 1,000.00 |
| Sep 30, 2022 | -86,000.00 |
| Mar 31, 2022 | 15.75 Mn |